(MedPage Today) — SAN FRANCISCO — Adjuvant durvalumab (Imfinzi) and tremelimumab (Imjudo) improved disease-free survival (DFS) in a phase III trial of resectable renal cell carcinoma (RCC), but researchers here said the regimen’s impact on…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
